BioConnection, a Dutch contract development manufacturing organization (CDMO), said that it has been selected by Nykode Therapeutics for manufacturing the aseptic drug product of its lead vaccine candidate.

Formerly Vaccibody, the Norway-based Nykode Therapeutics is a clinical stage biotech company focused on developing vaccines and novel immunotherapies for treating cancer as well as infectious diseases having a high unmet medical need.

Mette Husbyn — CTO of Nykode Therapeutics said: “We chose to partner with BioConnection for the manufacturing of Nykode’s precious clinical trial material because of their tailored solutions for production, matching the requirements for small scale batches.

“Moreover, BioConnection has an excellent broad manufacturing and regulatory track record, including EMA and FDA certification.”

BioConnection is engaged in producing sterile drug products in either vials or syringes for clinical trial programs as well as commercial purposes.

Alexander Willemse — BioConnection CEO said: “Phase I trials usually require small batches of drug products that have to be delivered in a precise manner. Capitalizing on our years of experience, we offer automated filling in large volumes up to 40 million vials per year, and importantly also manual fill and finish.

“I’m very happy that our manufacturing capabilities, perfectly match Nykode’s exact early phase clinical trial needs.”

  Alexander Willemse, BioConnection, Mette Husbyn, Norway, Nykode Therapeutics, The Netherlands, Vaccibody